Taltz is manufactured in the United States and shipped by courier from our pharmacy in India.
Information about Taltz (Ixekizumab)
Taltz (generic name: Ixekizumab) is a biologic medication used primarily to treat inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a monoclonal antibody that works by targeting and inhibiting interleukin-17A (IL-17A), a protein involved in the inflammatory response that plays a key role in these conditions. By blocking IL-17A, Taltz helps reduce inflammation, improve skin lesions in psoriasis, and relieve symptoms of joint pain in psoriatic arthritis.
Product Highlights
- Taltz is approved for the treatment of moderate-to-severe plaque psoriasis in adults who are eligible for systemic therapy or phototherapy.
- It is used to treat active psoriatic arthritis, either alone or alongside methotrexate, to reduce inflammation and enhance physical function.
- Taltz is approved to treat active ankylosing spondylitis, a condition that causes inflammation in the spine and other areas.
- Taltz may also be prescribed off-label for other inflammatory conditions involving IL-17A.
Key Ingredient
Key Benefits
- By inhibiting IL-17A, Taltz helps reduce the inflammation that causes symptoms in conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- Taltz has been proven to significantly enhance skin lesions and decrease the severity of psoriasis symptoms.
- In patients with psoriatic arthritis, Taltz can help reduce joint pain, stiffness, and swelling, improving mobility and overall function.
- Taltz offers a long duration of action, with the injection typically being administered every 4 to 12 weeks after the initial dosing period.
Direction of Use
- The dosing schedule is adjusted based on the condition being treated. For psoriasis, the initial doses are usually administered at weeks 0, 2, and 4, with a maintenance dose given every 4 weeks thereafter. For psoriatic arthritis and ankylosing spondylitis, dosing schedules may differ slightly based on the patient's response and condition.
- Taltz is given as a subcutaneous injection (under the skin), typically in the thigh or abdomen. For patients who are self-administering, a healthcare provider will provide training on proper injection technique.
- The medication should be stored in the refrigerator and never frozen. If necessary, it can be stored at room temperature for up to 30 days before use.
Safety Concerns
- Common side effects may include injection site reactions (such as redness, swelling, or discomfort), upper respiratory infections, headaches, and nausea.
- Serious side effects may include an increased risk of infections, including fungal, bacterial, or tuberculosis infections. There is also a risk of hypersensitivity reactions, including anaphylaxis.
- Patients using Taltz should be regularly monitored for signs of infections, and screenings for tuberculosis should be conducted before starting treatment.
- Taltz has not been studied extensively in pregnant or breastfeeding women, so it should only be used during pregnancy if clearly needed. Consult a doctor to evaluate the potential risks.
Avoid Taltz (Ixekizumab) If
- Do not use Taltz if you are allergic to ixekizumab or any of its components.
- Avoid using Taltz if you have a current active infection, including tuberculosis or any systemic fungal, bacterial, or viral infections.
- It should be used with caution during pregnancy and breastfeeding, and only if the benefits outweigh the risks, based on your healthcare provider’s recommendation.
- If you have a history of severe allergic reactions, including anaphylaxis, to similar medications, Taltz may not be suitable for you.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
